skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Gut microbiota: next frontier in understanding human health and development of biotherapeutics

Review

(1935) Views  (1135) Full article downloads

Authors: Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C

Published Date July 2011 Volume 2011:5 Pages 71 - 86
DOI: http://dx.doi.org/10.2147/BTT.S19099

Satya Prakash, Laetitia Rodes, Michael Coussa-Charley, Catherine Tomaro-Duchesneau
Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering and Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University, Montreal, Quebec, Canada

Abstract: The gut microbiota is a remarkable asset for human health. As a key element in the development and prevention of specific diseases, its study has yielded a new field of promising biotherapeutics. This review provides comprehensive and updated knowledge of the human gut microbiota, its implications in health and disease, and the potentials and limitations of its modification by currently available biotherapeutics to treat, prevent and/or restore human health, and future directions. Homeostasis of the gut microbiota maintains various functions which are vital to the maintenance of human health. Disruption of the intestinal ecosystem equilibrium (gut dysbiosis) is associated with a plethora of human diseases, including autoimmune and allergic diseases, colorectal cancer, metabolic diseases, and bacterial infections. Relevant underlying mechanisms by which specific intestinal bacteria populations might trigger the development of disease in susceptible hosts are being explored across the globe. Beneficial modulation of the gut microbiota using biotherapeutics, such as prebiotics, probiotics, and antibiotics, may favor health-promoting populations of bacteria and can be exploited in development of biotherapeutics. Other technologies, such as development of human gut models, bacterial screening, and delivery formulations eg, microencapsulated probiotics, may contribute significantly in the near future. Therefore, the human gut microbiota is a legitimate therapeutic target to treat and/or prevent various diseases. Development of a clear understanding of the technologies needed to exploit the gut microbiota is urgently required.

Keywords: gut microbiota, human health, dysbiosis, biotherapeutics, probiotics, microencapsulation






 

Other articles by Professor Satya Prakash

A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis
A novel polyethyleneimine-coated adeno-associated virus-like particle formulation for efficient siRNA delivery in breast cancer therapy: preparation and in vitro analysis
Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: investigation in rat heart with acute infarction
Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells
Diet-induced metabolic hamster model of nonalcoholic fatty liver disease
Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis
Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells
Mitotic and antiapoptotic effects of nanoparticles coencapsulating human VEGF and human angiopoietin-1 on vascular endothelial cells
Potentials and limitations of microorganisms as renal failure biotherapeutics


Readers of this article also read:

Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress
An update on belimumab for the treatment of lupus
A combined Phase I and II open-label study on the immunomodulatory effects of seaweed extract nutrient complex
The role of stem cells in tumor targeting and growth suppression of gliomas
Current neoadjuvant treatment options for HER2 positive breast cancer
Monoclonal antibodies and Fc fragments for treating solid tumors
Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) – a review of a new treatment paradigm
Role of vandetanib in the management of medullary thyroid cancer
Natural killer cells: role in local tumor growth and metastasis
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed